Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Reductions in Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: Results of a Long-term US Claims Database Analysis
P12 - Poster Session 12 (5:30 PM-6:30 PM)

Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP) pathway, is approved for preventive treatment of migraine in adults.

This US real-world, retrospective claims analysis evaluated health care resource utilization (HCRU) in patients with chronic or episodic migraine (CM/EM) for 12 months after first initiating fremanezumab treatment.

The IBM Marketscan Commercial and Medicare database identified adult patients (≥18 years) with ≥1 pharmacy claim for fremanezumab from September 1, 2018–March 31, 2019; ≥1 migraine diagnosis on or 12 months prior to the index date (date of earliest fremanezumab claim); and continuous enrollment for 12 months before (pre-index) and after (post-index) the index date. The study period was September 2017–March 2020. Patients who were pregnant during the study period were excluded. Baseline patient characteristics and overall/migraine-specific HCRU and associated costs were assessed 12 months pre- and post-initiation of fremanezumab.

2,354 eligible patients with migraine were identified. Most patients had EM (54%) and were female (86%); and mean[SD] age was 45.4[11.6] years. From 12 months pre-index to 12 months post-index, patients had statistically significant reductions in mean[SD] migraine-related emergency room (ER) visits (0.21[0.80] vs 0.15[0.96]) and total migraine-related outpatient visits (4.87[5.24] vs 4.38[5.02]; both P<0.0001). Mean[SD] migraine-related acute medication prescription claims decreased from 10.57[10.69] pre-index to 9.30[10.46] post-index (P<0.0001). Mean[SD] migraine-related costs decreased statistically significantly from 12 months pre-index to 12 months post-index, including migraine-related outpatient costs ($2,573.71[6,453.37] vs $2,485.70[7,112.81]), migraine-related acute medication costs ($1,346.46[3,124.83] vs $1,123.21[3,156.91]), and migraine-related ER costs ($292.41[1,280.84] vs $292.18[3,405.24]; all P<0.0001). Migraine-related inpatient visits and costs did not differ significantly pre- versus post-index.

Fremanezumab is associated with statistically significant reductions in migraine-related health care resource utilization and costs in the 12 months after first fremanezumab treatment initiation.


No disclosure on file
Maurice Driessen (Teva) No disclosure on file
Lynda Krasenbaum Lynda Krasenbaum has received personal compensation for serving as an employee of Teva Pharmaceuticals.
No disclosure on file
No disclosure on file
Michael Seminerio Michael Seminerio has received personal compensation for serving as an employee of AbbVie.